The U.S. Food and Drug Administration (FDA) approved a supplemental application for Kerendia (finerenone) on 2025-07-11. This approval, designated as NDA 215341 S-9, specifically relates to an update in the drug's efficacy information.
Background
Kerendia, also known by its generic name finerenone, is a drug developed by BAYER HLTHCARE. This supplemental application pertains to an update in the drug's efficacy profile, as reviewed by the FDA.
What this means
A supplemental approval for efficacy indicates that the FDA has reviewed new data supporting changes or additions to the drug's approved efficacy information. This could involve an expanded indication, a new patient population, or updated dosing recommendations based on new clinical evidence. Such approvals allow healthcare providers to use Kerendia in a refined or broader context, as supported by the latest scientific findings reviewed by the FDA.
Source
Information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA). The approval for supplemental application NDA 215341 S-9 for Kerendia (finerenone) was granted on 2025-07-11, as detailed on accessdata.fda.gov.